CAJ | 학술논문

目的观察缬沙坦联合舒洛地特对糖尿病肾病(DN)的疗效.方法将36例DN-Ⅲ期和36例DN-Ⅳ期患者随机分为三组:缬沙坦组、舒洛地特组、联合治疗组,每组12例,随访12周.比较治疗前后尿白蛋白排泄率(UAER)、24 h尿蛋白定量、血肌酐、血脂、血浆白蛋白的变化.结果治疗12周后,DN-Ⅲ期三组UAER、DN-Ⅳ期24h尿蛋白定量均有下降,两期中缬沙坦组与舒洛地特组比较差异均无统计学意义(P＞0.05),而与联合治疗组比较差异均有统计学意义(P＜0.05).结论缬沙坦联合舒洛地特能有效降低DN患者的尿蛋白,效果优于单一用药.
목적 관찰힐사탄연합서락지특대당뇨병신병(DN)적료효.방법 장36례DN-Ⅲ기화36례DN-Ⅳ기환자수궤분위삼조:힐사탄조、서락지특조、연합치료조,매조12례,수방12주.비교치료전후뇨백단백배설솔(UAER)、24 h뇨단백정량、혈기항、혈지、혈장백단백적변화.결과 치료12주후,DN-Ⅲ기삼조UAER、DN-Ⅳ기24h뇨단백정량균유하강,량기중힐사탄조여서락지특조비교차이균무통계학의의(P＞0.05),이여연합치료조비교차이균유통계학의의(P＜0.05).결론 힐사탄연합서락지특능유효강저DN환자적뇨단백,효과우우단일용약.
Objective To observe the effect of the combined therapy of valsartan and sulodexide on diabetic nephropathy(DN).Methods Thirty-six patients with DN-Ⅲ stage and thirty-six patients with DN-Ⅳ stage were randomized divided into valsartan group,sulodexide group,valsartan and sulodexide group,each group had 12 patients.The follow-up was 12 weeks.Then the UAER,24 h urinary protein,serum creatinine,blood lipid,plasma albumin were measured.Results After treatment of 12 weeks,the level of UAER of DN-Ⅲ stage and 24 h urinary protein of DN-Ⅳ stage decreased significantly in all the three groups,and no significant difference was observed between valsartan group and sulodexide group(P ＞ 0.05)in the two stages,but significant difference was noted compared with combined therapy group(P ＜ 0.05).Conclusions Valsartan combined with sulodexide can effectively decrease the level of urine protein in patients with DN and the effect is better than single application.